Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by PointState Capital LP

PointState Capital LP lessened its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 19.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,297,449 shares of the company's stock after selling 810,403 shares during the period. Roivant Sciences comprises 0.7% of PointState Capital LP's portfolio, making the stock its 28th largest holding. PointState Capital LP owned approximately 0.45% of Roivant Sciences worth $39,009,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Barclays PLC raised its position in shares of Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after buying an additional 75,609 shares during the last quarter. Elevate Capital Advisors LLC acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $2,116,000. Thompson Siegel & Walmsley LLC raised its position in shares of Roivant Sciences by 10.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after buying an additional 51,705 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Roivant Sciences during the fourth quarter worth approximately $995,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ROIV shares. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Roivant Sciences Stock Down 0.8%

ROIV opened at $10.67 on Thursday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The company has a 50 day moving average of $10.50 and a two-hundred day moving average of $11.09. The company has a market cap of $7.61 billion, a P/E ratio of -71.13 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 315,522 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the transaction, the chief operating officer now owns 959,457 shares of the company's stock, valued at approximately $10,611,594.42. This trade represents a 24.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. The trade was a 0.68% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,223,959 shares of company stock worth $13,420,035 in the last ninety days. 7.90% of the stock is owned by insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.